Probiotics, prebiotics, and digestive support compounds that nurture the gut microbiome and digestive wellness.
17 itemsDo lactase supplements actually help lactose intolerance? A focused look at what randomized trials, systematic reviews, and traditional practices suggest—plus where expectations should be set.
A focused look at how mushroom beta‑glucans interact with dectin‑1 and related receptors to modulate immunity, what human trials show, and why hot‑water vs dual extraction matters.
A focused, evidence-based guide to serum and fecal zonulin testing—what zonulin is, why many assays are unreliable, and how these tests compare with research-grade intestinal permeability measures.
A focused, evidence-based look at molecular mimicry as a gut-driven mechanism in Hashimoto’s thyroiditis—what’s known, what’s emerging, and how traditional perspectives align.
A focused, evidence‑based look at L‑glutamine for exercise‑induced gut permeability—what the research shows, how it ties to the gut–muscle axis, and where traditional practices like bone broth fit.
Psychobiotics—specific Lactobacillus and Bifidobacterium strains—may modestly improve mood and stress via the gut–brain axis. Learn what the evidence says, how the vagus nerve and fermented foods fit in, and where traditional ferments like kimchi, kefir, and miso meet modern science.
Glutamine sits at the crossroads of muscle, gut, and immune function. Here’s what research says about its role in athletic recovery, gut barrier integrity, immune health in athletes, burn/trauma care, and IBS—with a bridge to the traditional bone broth perspective.
An evidence-based look at how the gut may shape autoimmune risk and symptoms—covering mechanisms like molecular mimicry, microbiome diversity, anti-inflammatory diets (including AIP), and traditional perspectives from TCM and Ayurveda.
An evidence-based guide to how medicinal mushrooms may modulate immunity via beta‑glucans, with a look at reishi, turkey tail (PSK/PSP), chaga, cordyceps, lion’s mane, and why extraction methods matter—through both modern science and TCM lenses.
A clear-eyed look at “leaky gut”: what intestinal permeability is, how zonulin and tight junctions work, what’s accepted vs. debated, how testing is done, and which conventional and traditional approaches have evidence.
Targeted digestive enzymes can help specific intolerances—lactase for lactose and alpha-galactosidase for bean-related gas—while broad blends and betaine HCl have limited evidence. Prescription pancreatic enzymes are effective for true pancreatic insufficiency. Traditional aids like ginger, bitters, and CCF tea may complement modern strategies.
Lactobacillus, Bifidobacterium, soil-based — which probiotic strains have real evidence, how to combine with prebiotics, and common mistakes to avoid.
Type I, II, III — not all collagen is the same. Which forms actually work, optimal dosing, and how to pair collagen with vitamin C for absorption.
Live beneficial bacteria that support gut microbiome health, digestion, and immune function.
Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain and altered bowel habits without structural disease. Under the Rome IV criteria, IBS is defined by abdominal pain, on average, at least one day per week in the last three months, associated with two or more of the following: related to defecation, change in stool frequency, or change in stool form; symptoms start at least six months before diagnosis. Subtypes are based on predominant stool pattern: IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), mixed (IBS-M), or unclassified. Western medicine frames IBS as a multifactorial condition involving disordered gut–brain signaling, visceral hypersensitivity, altered motility, immune activation, psychosocial stressors, and microbiome perturbations. Evidence-based care is individualized and multimodal. Diet is foundational: the low-FODMAP diet—developed and validated by Monash University—has strong evidence for improving global IBS symptoms when delivered in a structured, three-phase format (short-term elimination, personalized reintroduction, and long-term adaptation). Pharmacotherapies target stool form and pain: antispasmodics (e.g., hyoscine, dicyclomine) can reduce cramping; rifaximin is effective for IBS-D; and secretagogues such as linaclotide and plecanatide are effective for IBS-C. Low-dose tricyclic antidepressants (TCAs) and, in selected cases, SSRIs modulate the gut–brain axis to reduce pain and normalize bowel habits. Psychological therapies—especially gut-directed cognitive behavioral therapy (CBT)—have strong support for improving global symptoms and quality of life. Emerging approaches include selective probiotics, postbiotics, and microbiome-directed therapies; evidence is mixed and evolving, and current guidelines are cautious about routine probiotic use for global IBS symptoms due to heterogeneity. Eastern and traditional systems conceptualize IBS through functional patterns.
Irritable bowel syndrome (IBS) is a chronic, relapsing disorder of gut–brain interaction characterized by abdominal pain associated with altered bowel habits, without structural disease that explains the symptoms. Western medicine classifies IBS using the Rome IV criteria: recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following—related to defecation, associated with a change in frequency of stool, and associated with a change in form (appearance) of stool—with symptom onset at least 6 months before diagnosis. Subtypes are defined by predominant stool pattern: diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), mixed (IBS-M), and unclassified. Pathophysiology is multifactorial: visceral hypersensitivity, altered motility, immune activation and barrier dysfunction, dysbiosis, bile acid malabsorption in a subset, and central modulation via the gut–brain axis. Psychosocial stressors and early life adversity can amplify symptoms through bidirectional brain–gut signaling. Evidence-based Western management is multimodal and personalized. First-line lifestyle strategies include regular physical activity, sleep optimization, and diet. The low-FODMAP diet—temporary restriction of fermentable oligo-, di-, monosaccharides and polyols—has strong evidence for reducing global IBS symptoms when delivered in a structured elimination and reintroduction program (best studied by Monash University). Soluble fiber (psyllium) is recommended in IBS-C and some mixed phenotypes, while insoluble fiber may worsen symptoms. Pharmacologic options are matched to subtype and dominant symptoms: antispasmodics (e.g., dicyclomine, hyoscyamine) for cramping; loperamide for urgency/diarrhea control (not for global symptom relief); bile acid sequestrants in suspected bile acid diarrhea; non-absorbed antibiotic rifaximin for IBS-D; secretagogues such as linaclotide and plecanatide for IBS-C; lubiprostone (women with IBS
IBS and anxiety frequently travel together through a shared gut–brain axis. IBS is a disorder of gut–brain interaction defined by recurrent abdominal pain with altered bowel habits, while anxiety e...
